Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2021

View Archived Issues

Positive interim data from phase I study of ALT-801 in overweight and obese volunteers

SpringWorks initiates phase I/II study of mirdametinib in children and young adults with LGG

Infex Therapeutics discloses new antibacterials

VenatoRx Pharmaceuticals synthesizes new carbapenem derivatives

Janssen Pharmaceutica presents new Mcl-1 inhibitors

Dunad Therapeutics and 2692372 Ontario, Inc. patent compounds for cancer

Japansese researchers describe new delta-opioid receptor agonists

Preclinical data for NVG-111: a ROR1xCD3 bispecific antibody

Second patient dosed in phase I/II MARVEL-1 study of FLT-190 in Fabry disease

Switching on prodrugs with radiotherapy shows promise

Paratek opens phase IIb study of Nuzyra in M. abscessus pulmonary disease

MacroGenics and Zai Lab collaborate on bispecific molecules in immuno-oncology

Safety data presented for BGB-11417 in R/R B-cell malignancies

Phase I/II trial of eprenetapopt in TP53-mutant AML meets primary efficacy endpoint

DSMB recommends phase I trial of rhenium nanoliposomes in GBM proceed to next cohort

Mydecine launches in silico drug discovery program with University of Alberta

Topline data from phase I study of NASH drug candidate ASC-42

Debiopharm and Ubix collaborate to develop antibody degraducer conjugates

CHN1 is a prognostic biomarker in DLBCL

Interim phase IIb/III data on CVnCoV show statistical success criteria not met

Apexigen and NSGO-CTU to collaborate on phase II study of sotigalimab for ovarian cancer

China's NMPA approves initiation of clinical trials of anti-Claudin 18.2 ADC SYSA-1801

Therapeutic Solutions reports preclinical data on low-dose naltrexone for schizophrenia

Early phase I data presented for LVGN-6051 as monotherapy and in combination with pembrolizumab

Loss of RKIP tied to aggressiveness in HNSCC

Biogen discontinues gosuranemab based on phase II data in Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...